Rocket Lab SEC Filings

This Form 144 discloses Rocket Lab officer Adam C. Spice's intent to sell 874,588 common shares acquired via option exercise on September 18, 2025. The shares have an aggregate market value of $41,985,296.61, representing about 0.18% of outstanding shares. Investors should note this routine insider sale post-exercise, with no prior sales in the past three months.

Arjun Kampani, SVP General Counsel, sold 40,601 shares of RKLB on Sep 16-17, 2025, through multiple transactions. Sales consisted of sell-to-cover for RSU vesting taxes and automatic 10b5-1 plan executions. Neutral signal due to pre-planned, non-discretionary nature.

Frank Klein, Chief Operations Officer at Rocket Lab USA, executed multiple sales totaling 49,821 shares on Sept 16-17, 2025. Most were sell-to-cover transactions for tax withholding on RSU vesting, with the remainder under a Rule 10b5-1 plan adopted in Dec 2024. This is a neutral signal, as the sales are routine and non-discretionary.

Chief Financial Officer Adam C. Spice executed multiple sell-to-cover sales totaling 68,254 shares of RKLB common stock on 09/16/2025 at prices from $47.79-$51.63. These were to cover tax withholding on vesting restricted stock units. Signal is neutral, as routine non-discretionary.

Director Matthew Ocko, through managed VC funds DCVC IV and DCVC Opportunity Fund II, sold 1.87M shares in multiple open-market tranches on 9/16/2025 at weighted prices from $47.49 to $52.23, totaling ~$90M. Funds then distributed all remaining shares pro rata to partners. Bearish signal due to large discretionary liquidation without 10b5-1 plan.

Form 144 discloses Rocket Lab officer Arjun Kampani's intent to sell 9,416 common shares acquired from RSUs vesting on 08/22/2025, valued at $444,859. Sale set for 09/17/2025 via Morgan Stanley under Rule 10b5-1 plan adopted 12/12/2024; no sales in past 3 months. Relevant for investors tracking insider activity amid RKLB's growth trajectory.

Form 144 discloses Rocket Lab officer Frank Klein's intent to sell 4,286 common shares (market value $202,492) acquired via RSUs vested on 08/22/2025. Sale pursuant to Rule 10b5-1 plan adopted 12/13/2024; no prior sales in past 3 months. Routine insider liquidity event relevant for monitoring executive compensation realization.

Peter Beck, President, CEO & Chairman, via Equatorial Trust sold 2,500,000 RKLB shares on 9/15-16/2025 at avg prices $48.04-$54.96. Sales executed automatically under Rule 10b5-1 plan adopted 6/13/2025. Neutral signal due to pre-planned nature.

Rocket Lab Corp officer Arjun Kampani filed Form 144 on 2025-09-16 for proposed sale of 31,185 common shares (22,991 + 8,194) valued at ~$1.53M. Shares stem from vesting of 52,471 RSUs on 2025-09-15 as compensation, with sales covering tax obligations via broker Morgan Stanley. No sales reported in prior 3 months; routine sell-to-cover transaction.

This Form 144 discloses Rocket Lab officer Frank Klein's intent to sell 45,535 common shares (market value $2.23M) via Morgan Stanley, acquired via 81,250 RSUs vesting on 09/15/2025 as compensation. The sale covers tax obligations from the vesting. No prior sales in past 3 months; routine insider transaction.